Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hong Kong Government Explores Alternatives To Capping Public Health Care Costs

This article was originally published in The Pink Sheet Daily

Executive Summary

Six funding alternatives include social health insurance, out-of-pocket payments, medical savings accounts, voluntary or mandatory health insurance and personal health care reserves.

You may also be interested in...

Hong Kong Pharmaceutical Industry Association Executive Director Sabrina Chan On Competition and R&D in Hong Kong: An Interview with PharmAsia News (Part 2 of 2)

Hong Kong, with a population of just under 7 million and long known for its status as one of the most open markets in the world, can be a challenging market for pharma companies because roughly half of the drugs sold in the Special Administrative Region of China go through its Hospital Authority. It can take up to three years to get an approved product on its list of available products. The Hong Kong Association of the Pharmaceutical Industry, which represents 42 companies including multinational companies that operate in Hong Kong, is fighting to cut through the red tape and get innovative drugs to patients faster while trying to stay on top of a stubborn counterfeit problem, Executive Director Sabrina Chan told PharmAsia News' Hong Kong bureau in an exclusive interview.

Southeast Asian Regulators Ramp Up Anti-Corruption, Bribery Enforcement Ahead of ASEAN Pact

Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.

St. Jude Introduces Allure Quadra To Hong Kong As It Seeks APAC Rebound For Pacemakers

The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts